Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VISHAL K BHAGAT

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1649364381
CMS profile
119707
Location
ROANOKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,938.68

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $3,600.00 1
Travel and Lodging $952.10 3
Food and Beverage $386.58 7

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Intercept Pharmaceuticals, Inc. $4,938.68 11

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VISHAL K BHAGAT

NPI 1649364381 · CMS profile ID 119707

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ROANOKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649364381?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649364381?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649364381?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
VISHAL K BHAGAT, NPI 1649364381, CMS profile ID 119707, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1649364381?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $4,938.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Intercept Pharmaceuticals, Inc. $3,600.0003/12/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844311 CMS
Intercept Pharmaceuticals, Inc. $35.0403/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844313 CMS
Intercept Pharmaceuticals, Inc. $20.6903/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844319 CMS
Intercept Pharmaceuticals, Inc. $34.0903/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844305 CMS
Intercept Pharmaceuticals, Inc. $27.8602/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844289 CMS
Intercept Pharmaceuticals, Inc. $49.9902/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844295 CMS
Intercept Pharmaceuticals, Inc. $42.1302/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844297 CMS
Intercept Pharmaceuticals, Inc. $282.5002/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844303 CMS
Intercept Pharmaceuticals, Inc. $120.0002/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844287 CMS
Intercept Pharmaceuticals, Inc. $77.4702/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844281 CMS
Intercept Pharmaceuticals, Inc. $648.9102/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739844279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $509.08 7
PY2020 $4,938.68 11
PY2021 $32.27 1
PY2022 $75.82 5
PY2023 $919.12 40
PY2024 $2,031.07 67
PY2025 $1,991.66 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,849.40 2
PY2025 Principal investigator $55,610.00 40
PY2024 Principal investigator $62,278.00 40
PY2023 Principal investigator $8,000.00 1
PY2021 Principal investigator $102,250.00 536
PY2020 Principal investigator $199,035.36 32
PY2019 Principal investigator $310,985.31 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $121,125.76 12/31/2019 Non-covered Recipient Entity
PARAGON INTERNATIONAL INC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670126223
Principal investigator 1 Allergan Inc. $14,482.75 12/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWEST VIRGINI
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670116483
Principal investigator 1 Allergan Inc. $4,104.00 10/22/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670088179
Principal investigator 1 Allergan Inc. $14,468.50 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086079
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086411
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086471
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086501
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086542
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086618
Principal investigator 1 Allergan Inc. $45.00 10/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670086647
Principal investigator 1 Dova Pharmaceuticals $540.00 10/16/2019 Non-covered Recipient Entity
The Copernicus Group Inc dba Copernicus Group IRB
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420787
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084579
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084667
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084765
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084769
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084831
Principal investigator 1 Allergan Inc. $430.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084929
Principal investigator 1 Allergan Inc. $430.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670084933
Principal investigator 1 Allergan Inc. $5,000.00 10/15/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670085021
Principal investigator 1 Allergan Inc. $2,052.00 09/24/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670079485
Principal investigator 1 Allergan Inc. $6,251.00 09/19/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670077423
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075701
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075725
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075734
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075739
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075771
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075793
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075797
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075801
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075807
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075895
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075917
Principal investigator 1 Allergan Inc. $45.00 09/17/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670075919
Principal investigator 1 Allergan Inc. $5,000.00 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074835
Principal investigator 1 Allergan Inc. $5,000.00 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074863
Principal investigator 1 Allergan Inc. $430.00 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074887
Principal investigator 1 Allergan Inc. $2,752.50 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074893
Principal investigator 1 Allergan Inc. $430.00 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074897
Principal investigator 1 Allergan Inc. $430.00 09/12/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074929
Principal investigator 1 Allergan Inc. $22,059.00 08/13/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670064575
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059797
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059827
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059839
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059871
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059913
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059917
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670059923
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060104
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060151
Principal investigator 1 Allergan Inc. $430.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060155
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060159
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060193
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060197
Principal investigator 1 Allergan Inc. $5,000.00 07/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670060203
Principal investigator 1 Allergan Inc. $15,000.00 04/23/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670040295
Principal investigator 1 Allergan Inc. $430.00 04/18/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038161
Principal investigator 1 Allergan Inc. $500.00 04/18/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038243
Principal investigator 1 Allergan Inc. $1,290.00 04/18/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038283
Principal investigator 1 Allergan Inc. $9,000.00 04/18/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038345
Principal investigator 1 Allergan Inc. $5,000.00 04/18/2019 Non-covered Recipient Entity
GASTROENTEROLOGY CONSULTANTS OF SOUTHWES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670038363
Principal investigator 1 Dova Pharmaceuticals $250.00 04/03/2019 Non-covered Recipient Entity
The Copernicus Group Inc dba Copernicus Group IRB
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420727
Principal investigator 1 Dova Pharmaceuticals $740.00 02/14/2019 Non-covered Recipient Entity
Gastroenterology Consultants of Southwes
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420531
Principal investigator 1 Dova Pharmaceuticals $5,399.80 02/14/2019 Non-covered Recipient Entity
Gastroenterology Consultants of Southwes
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420533